ArticleCNS neuroscience & therapeutics2026
Circulating Serum AGRN and ADAMTS8 With Related Candidates as Potential Biomarkers for Carotid Plaque Presence and Vulnerability.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundCarotid atherosclerosis is a major etiologic substrate for ischemic stroke. Although imaging can characterize stenosis and plaque morphology, circulating biomarkers may better support screening and scalable risk stratification, yet reliable serum protein markers for carotid plaque, particularly for plaque instability, remain limited.
methodsWe enrolled 128 participants, including patients with stable plaques (n = 41), unstable plaques (n = 49), and healthy controls (n = 38). Plaque stability was determined by carotid ultrasonography. We prespecified a serum biomarker panel comprising seven proteins and measured all of them: agrin (AGRN), ADAMTS8, ADAMTS9, collagen type XVIII alpha 1 chain (COL18A1), integrin subunit beta 4 (ITGB4), lysyl oxidase like 4 (LOXL4), and slit guidance ligand 3 (SLIT3). All proteins were quantified by enzyme-linked immunosorbent assay (ELISA). Group comparisons were performed with multiple-comparison adjustment. Receiver operating characteristic (ROC) analyses and the area under the curve (AUC) evaluated the ability of individual biomarkers and the combined prediction probability to discriminate plaque presence and plaque instability.
resultsBaseline characteristics differed substantially between plaque groups and healthy controls. Serum AGRN concentrations were significantly elevated in plaque patients versus controls (mean ± SD, Stable: 2222.42 ± 508.30 pg/mL; Unstable: 2109.59 ± 513.51 pg/mL; Healthy: 1800.36 ± 375.89 pg/mL; overall p < 0.001), while ADAMTS8 levels were comparable across groups (overall p = 0.110). In multivariable Firth penalized logistic regression with log2-transformed biomarkers, neither AGRN nor ADAMTS8 was independently associated with plaque presence or plaque instability after adjustment for age, sex, hypertension, alcohol use, dyslipidemia, smoking, diabetes mellitus, and coronary heart disease (all adjusted p > 0.05). For discriminating plaque presence, the combined AGRN+ADAMTS8 model achieved an apparent AUC of 0.771 (bootstrap 95% CI, 0.678-0.865; optimism-corrected AUC, 0.764; repeated stratified 5-fold cross-validated AUC, 0.749). For plaque instability, the combined model showed no discriminatory capacity (apparent AUC, 0.549; optimism-corrected AUC, 0.498; repeated 5-fold cross-validated AUC, 0.471).
conclusionsCirculating AGRN and ADAMTS8, measured as serum concentrations, are associated with carotid plaque presence versus healthy controls but do not independently discriminate plaque presence or instability after multivariable adjustment. Clinical covariates alone (age, sex, vascular risk factors) provided near-perfect discrimination of plaque presence, indicating substantial spectrum bias arising from the healthy-control comparator design. These findings underscore the need for age- and risk-matched comparator populations in future biomarker studies, consistent with STARD 2015 recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.